US2011065641A1PendingUtilityA1

Polypeptide and dna thereof useful as a neovascular marker

47
Assignee: SHIONOGI & COPriority: May 7, 2001Filed: Nov 19, 2010Published: Mar 17, 2011
Est. expiryMay 7, 2021(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/00A61P 35/00A61P 29/00A61P 25/00A61P 27/02A61K 38/00C12Q 1/6883C12Q 2600/158C07K 14/47A61P 15/00C12N 2799/026G01N 33/53
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.

Claims

exact text as granted — not AI-modified
1 . A method for inhibiting proliferation of vascular endothelial cells comprising administering a composition comprising the polypeptide KIAA 1036 to said vascular endothelial cells. 
     
     
         2 . The method of  claim 1 , in which the composition is administered to a subject. 
     
     
         3 . The method of  claim 1 , in which the composition is administered to cells in culture. 
     
     
         4 . The method of  claim 2 , in which the subject presents with entoptic neovascularization, colon cancer, or ovarian cancer. 
     
     
         5 . A method for preventing angiogenesis comprising administering a composition comprising the polypeptide KIAA 1036 to vascular endothelial cells. 
     
     
         6 . The method of  claim 5 , in which the composition is administered to a subject. 
     
     
         7 . The method of  claim 5 , in which the composition is administered to vascular endothelial cells in culture. 
     
     
         8 . The method of  claim 6 , in which the subject presents with entoptic neovascularization, colon cancer or ovarian cancer.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.